Table 2.
Frequency of antiretroviral therapy (ART) resistance mutations among participants with viral load ≥ 1000 copies/mL (n = 105)
| n | % | |
|---|---|---|
| ART class mutations | ||
| NNRTI resistance mutations | 98 | 93.3 |
| PI resistance mutations | 1 | 1.0 |
| NRTI resistance mutations | 100 | 95.2 |
| TAMs | 69 | 65.7 |
| Other NRTI resistance mutations | 31 | 29.5 |
| Individual mutations | ||
| M184V | 95 | 90.5 |
| Y181C | 42 | 40.0 |
| K103N | 36 | 34.3 |
| M41 l* | 34 | 32.4 |
| T215Y* | 30 | 28.6 |
| K70R* | 25 | 23.8 |
| G190A | 23 | 21.9 |
| L210W* | 21 | 20.0 |
| T215F* | 19 | 18.1 |
| D67N* | 18 | 17.1 |
| K219Q* | 15 | 14.3 |
| K219E* | 13 | 12.4 |
| K65R | 12 | 11.4 |
| K101E | 7 | 6.7 |
| P225H | 6 | 5.7 |
| Others | 33 | 31.4 |
NNRTI, nonnucleoside reverse transcriptase inhibitor; NRTI, nucleoside reverse transcriptase inhibitor; PI, protease inhibitor; TAM, thymidine analogue mutation.